A step by step approach in differential diagnosing of adrenal incidentaloma (epinephroma), (with comments on the new Clinical Practice Guidelines of the European Society of Endocrinology)

1. UDELSMAN R. ADRENAL. In: Norton A J, Bollinger RR, editors. Surgery, Basic Science and Clinical Evidence: Springer; 2001, p. 902.Search in Google Scholar

2. BULOW B, JANSSON S, JUHLIN C, STEEN L, THOREN M, WAHRENBERG H, et al. Adrenal incidentaloma – follow-up results from a Swedish prospective study. Eur J Endocrinol 2006; 154 (3):419-23.10.1530/eje.1.0211016498055Search in Google Scholar

3. ANAGNOSTIS P, KARAGIANNIS A, TZIOMALOS K, KAKAFIKA AI, ATHYROS VG, MIKHAILIDIS DP. Adrenal incidentaloma: a diagnostic challenge. Hormones (Athens) 2009; 8 (3):163-84.10.14310/horm.2002.123319671516Search in Google Scholar

4. GRUMBACH MM, BILLER BM, BRAUNSTEIN GD, CAMPBELL KK, CARNEY JA, GODLEY PA, et al. Management of the clinically inapparent adrenal mass (adrenal incidentaloma). Annals of Internal Medicine 2003; 138 (5):424-429.10.7326/0003-4819-138-5-200303040-0001312614096Search in Google Scholar

5. FASSNACHT M, ARLT W, BANCOS I, DRALLE H, NEWELL-PRICE J, SAHDEV A, et al. Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors. European Journal of Endocrinology 2016; 175 (2):G1-G34.10.1530/EJE-16-046727390021Search in Google Scholar

6. PAPIERSKA L, CICHOCKI A, SANKOWSKI AJ, CWIKLA JB. Adrenal incidentaloma imaging - the first steps in therapeutic management. Pol J Radiol 2013; 78 (4):47-55.10.12659/PJR.889541390850724505223Search in Google Scholar

7. LINOS DA. Adrenal incidentaloma (adrenaloma). Hormones (Athens) 2003; 2 (1):12-21.10.14310/horm.2002.117817002998Search in Google Scholar

8. GEELHOED GW, DRUY EM. Management of the adrenal “incidentaloma”. Surgery 1982; 92 (5):866-74.Search in Google Scholar

9. GOVE PB. Webster’s third new international dictionary of the English language, unabridged: Merriam-Webster; 2002.Search in Google Scholar

10. FARRUGIA FA, MARTIKOS G, TZANETIS P, ZAVRAS N, CHARALAMPOPOULOS A, SOTIROPOULOS D, et al. Adrenal incidentaloma or epinephroma and review of the literature. Differential Diagnosis of Adrenal Incidentaloma. Khirurgiia 2016; October (3):120-129.Search in Google Scholar

11. DIVRY DBC. English-Greek and Greek English Handy Dictionary. In Revised Edition ed. New York: D.C. Divry, Inc., Publishers; 1994, p. 326.Search in Google Scholar

12. WARDA MHA, SHEHATA SM, ZAITON F. Chemical-shift MRI versus washout CT for characterizing adrenal incidentalomas. Clinical Imaging 2016; 40 (4):780-787.10.1016/j.clinimag.2016.02.00627317224Search in Google Scholar

13. YIP L, TUBLIN ME, FALCONE JA, NORDMAN CR, STANG MT, OGILVIE JB, et al. The adrenal mass: correlation of histopathology with imaging. Annals of surgical oncology 2010; 17 (3):846-852.10.1245/s10434-009-0829-219960266Search in Google Scholar

14. SEO JM, PARK BK, PARK SY, KIM CK. Characterization of lipid-poor adrenal adenoma: chemical-shift MRI and washout CT. American Journal of Roentgenology 2014; 202 (5):1043-1050.10.2214/AJR.13.1138924758658Search in Google Scholar

15. SCHIEDA N, SIEGELMAN ES. Update on CT and MRI of Adrenal Nodules. American Journal of Roentgenology 2017:1-12.10.2214/AJR.16.1775828225653Search in Google Scholar

16. ZEIGER MA, THOMPSON GB, DUH Q-Y, HAMRAHIAN AH, ANGELOS P, ELARAJ D, et al. American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocrine Practice 2009; 15:1-20.10.4158/EP.15.S1.1Search in Google Scholar

17. DEFECHEREUX T, DEGAUQUE C, HAMOIR E, LAMBERTY G, PREUD’HOMME L, MEURISSE M. [Discordance between actual and radiologically estimated size of an incidentaloma. Delay in questions regarding operative decision-making criteria]. Ann Chir 2002; 127 (2):126-9.10.1016/S0003-3944(01)00705-2Search in Google Scholar

18. PAPIERSKA L, CICHOCKI A, SANKOWSKI AJ, CWIKLA JB. Adrenal incidentaloma imaging – the first steps in therapeutic management. Pol J Radiol; 78 (4):47-55.10.12659/PJR.889541390850724505223Search in Google Scholar

19. REGINELLI A, DI GREZIA G, IZZO A, DΒ€™ANDREA A, GATTA G, CAPPABIANCA S, et al. Imaging of adrenal incidentaloma: Our experience. International Journal of Surgery 2014; 12:S126-S131.10.1016/j.ijsu.2014.05.02924862667Open DOISearch in Google Scholar

20. MORELLI V, SCILLITANI A, AROSIO M, CHIODINI I. Follow-up of patients with adrenal incidentaloma, in accordance with the European Society of Endocrinology guidelines: Could we be safe? Journal of Endocrinological Investigation 2016:1-3.10.1007/s40618-016-0558-x27744612Search in Google Scholar

21. CHIODINI I, ALBANI A, AMBROGIO AG, CAMPO M, DE MARTINO MC, MARCELLI G, et al. Six controversial issues on subclinical Cushing’s syndrome. Endocrine 2016:1-5.10.1007/s12020-016-1017-327406391Search in Google Scholar

22. CHIODINI I, MORELLI V. Subclinical hypercortisolism: how to deal with it? In: Cortisol Excess and Insufficiency: Karger Publishers; 2016, 28-38.10.1159/00044386227212038Search in Google Scholar

23. PAPIERSKA L, CICHOCKI A, SANKOWSKI AJ, CWIKLA JB. Adrenal incidentaloma imaging-the first steps in therapeutic management. Polish Journal of Radiology 2013; 78 (4):47.10.12659/PJR.889541Search in Google Scholar

24. MANTERO F, TERZOLO M, ARNALDI G, OSELLA G, MASINI AM, ALI A, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000; 85 (2):637-44.Search in Google Scholar

25. TABUCHI Y, OTSUKI M, KASAYAMA S, KOSUGI K, HASHIMOTO K, YAMAMOTO T, et al. Clinical and endocrinological characteristics of adrenal incidentaloma in Osaka region, Japan. Endocrine journal 2015 (0).Search in Google Scholar

26. SONG JH, GRAND DJ, BELAND MD, CHANG KJ, MACHAN JT, MAYO-SMITH WW. Morphologic features of 211 adrenal masses at initial contrast-enhanced CT: can we differentiate benign from malignant lesions using imaging features alone? American Journal of Roentgenology 2013; 201 (6):1248-1253.Search in Google Scholar

27. ILIAS I, SAHDEV A, REZNEK RH, GROSSMAN AB, PACAK K. The optimal imaging of adrenal tumours: a comparison of different methods. Endocrine-Related Cancer 2007; 14 (3):587-599.10.1677/ERC-07-004517914090Search in Google Scholar

28. DUNNICK NR, KOROBKIN M. Imaging of adrenal incidentalomas: current status. American Journal of Roentgenology 2002; 179 (3):559-568.10.2214/ajr.179.3.179055912185019Search in Google Scholar

29. LOCKHART ME, SMITH JK, KENNEY PJ. Imaging of adrenal masses. European journal of radiology 2002; 41 (2):95-112.10.1016/S0720-048X(01)00444-2Open DOISearch in Google Scholar

30. YOUNG JR WF. The incidentally discovered adrenal mass. New England Journal of Medicine 2007; 356 (6):601-610.10.1056/NEJMcp06547017287480Search in Google Scholar

31. ZEIGER MA, SIEGELMAN SS, HAMRAHIAN AH. Medical and surgical evaluation and treatment of adrenal incidentalomas. The Journal of Clinical Endocrinology & Metabolism 2011; 96 (7):2004-2015.10.1210/jc.2011-008521632813Open DOISearch in Google Scholar

32. MANSMANN G, LAU J, BALK E, ROTHBERG M, MIYACHI Y, BORNSTEIN SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocrine reviews 2004; 25 (2):309-340.10.1210/er.2002-003115082524Open DOISearch in Google Scholar

33. BEDNARCZUK T, BOLANOWSKI M, SWORCZAK K, GORNICKA B, CIESZANOWSKI A, OTTO M, et al. Adrenal incidentaloma in adults’ management recommendations by the Polish Society of Endocrinology. Endokrynologia Polska 2016; 67 (2):234.10.5603/EP.a2016.003927082051Search in Google Scholar

34. FRANCIS IR. Distinguishing benign from malignant adrenal masses. Cancer Imaging 2015; 3 (2):102.Search in Google Scholar

35. MAYO-SMITH W, LEE M, MCNICHOLAS M, HAHN P, BOLAND G, SAINI S. Characterization of adrenal masses (< 5 cm) by use of chemical shift MR imaging: observer performance versus quantitative measures. AJR. American Journal of Roentgenology 1995; 165 (1):91-95.10.2214/ajr.165.1.77856427785642Search in Google Scholar

36. BILBEY JH, MCLOUGHLIN R, KURKJIAN P, WILKINS G, CHAN N, SCHMIDT N, et al. MR imaging of adrenal masses: value of chemical-shift imaging for distinguishing adenomas from other tumors. AJR. American Journal of Roentgenology 1995; 164 (3):637-642.10.2214/ajr.164.3.78638857863885Search in Google Scholar

37. MIYAKE H, MAEDA H, TASHIRO M, SUZUKI K, NAGATOMO H, AIKAWA H, et al. CT of adrenal tumors: frequency and clinical significance of low-attenuation lesions. American Journal of Roentgenology 1989; 152 (5):1005-1007.10.2214/ajr.152.5.10052705336Search in Google Scholar

38. BLAKE MA, KRISHNAMOORTHY SK, BOLAND GW, SWEENEY AT, PITMAN MB, HARISINGHANI M, et al. Lowdensity pheochromocytoma on CT: a mimicker of adrenal adenoma. American Journal of Roentgenology 2003; 181 (6):1663-1668.10.2214/ajr.181.6.181166314627592Search in Google Scholar

39. ARNALDI G, MASINI A, GIACCHETTI G, TACCALITI A, FALOIA E, MANTERO F. Adrenal incidentaloma. Brazilian Journal of Medical and Biological Research 2000; 33 (10):1177-1189.10.1590/S0100-879X2000001000007Search in Google Scholar

40. LOU I, SCHNEIDER DF, LEVERSON GE, SIPPEL RS, CHEN H. Do additional imaging studies change operative management in patients undergoing adrenalectomy? Surgery 2015; 158 (4):1003-1011.Search in Google Scholar

41. NIH state-of-the-science statement on management of the clinically inapparent adrenal mass (“incidentaloma”). NIH Consens State Sci Statements 2002; 19 (2):1-25.Search in Google Scholar

42. BOLAND GW, BLAKE MA, HAHN PF, MAYO-SMITH WW. Incidental Adrenal Lesions: Principles, Techniques, and Algorithms for Imaging Characterization 1. Radiology 2008; 249 (3):756-775.10.1148/radiol.249307097619011181Search in Google Scholar

43. MAYO-SMITH WW, BOLAND GW, NOTO RB, LEE MJ. State-of-the-art adrenal imaging. Radiographics 2001; 21 (4):995-1012.10.1148/radiographics.21.4.g01jl2199511452074Open DOISearch in Google Scholar

44. LEE JK. Computed body tomography with MRI correlation: Lippincott Williams & Wilkins, 1998.Search in Google Scholar

45. KRESTIN GP, STEINBRICH W, FRIEDMANN G. Adrenal masses: evaluation with fast gradient-echo MR imaging and Gd-DTPA-enhanced dynamic studies. Radiology 1989; 171 (3):675-680.10.1148/radiology.171.3.27177372717737Search in Google Scholar

46. CONDER G, RENDLE J, KIDD S, MISRA RR. AZ of Abdominal Radiology. Cambridge University Press; 2009. p. 28-37.10.1017/CBO9780511575792Search in Google Scholar

47. SCHTEINGART D, DOHERTY G, GAUGER P, GIORDANO T, HAMMER G, KOROBKIN M, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocrine-Related Cancer 2005; 12 (3):667-680.10.1677/erc.1.0102916172199Open DOISearch in Google Scholar

48. ELSAYES KM, MUKUNDAN G, NARRA VR, LEWIS JR JS, SHIRKHODA A, FAROOKI A, et al. Adrenal Masses: MR Imaging Features with Pathologic Correlation 1. Radiographics 2004; 24 (suppl_1):S73-S86.10.1148/rg.24si04551415486251Open DOISearch in Google Scholar

49. FIEBRICH H-B, BROUWERS AH, KERSTENS MN, PIJL ME, KEMA IP, DE JONG JR, et al. 6-[F-18] Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with 123I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. The Journal of Clinical Endocrinology & Metabolism 2009; 94 (10):3922-3930.10.1210/jc.2009-105419622618Search in Google Scholar

50. SUNDIN A. Imaging of adrenal masses with emphasis on adrenocortical tumors. Theranostics 2012; 2 (5):516-22.10.7150/thno.3613336455722737189Search in Google Scholar

51. Dorland. Dorland’s Illustrated Medical Dictionary. 32 ed: Saunders, 2007.Search in Google Scholar

52. LENDERS JW, PACAK K, WALTHER MM, LINEHAN WM, MANNELLI M, FRIBERG P, et al. Biochemical diagnosis of pheochromocytoma: which test is best? Jama 2002; 287 (11):1427-1434.Search in Google Scholar

53. IACOBONE M, CITTON M, SCARPA M, VIEL G, BOSCARO M, NITTI D. Systematic review of surgical treatment of subclinical Cushing’s syndrome. British Journal of Surgery 2015; 102 (4):318-330.10.1002/bjs.974225640696Search in Google Scholar

54. THOMAS AZ, BLUTE ML, SEITZ C, HABRA MA, KARAM JA. Management of the incidental adrenal mass. European Urology Focus 2016; 1 (3):223-230.10.1016/j.euf.2015.12.00628723391Search in Google Scholar

55. FUNDER JW, CAREY RM, FARDELLA C, GOMEZ-SANCHEZ CE, MANTERO F, STOWASSER M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism 2008; 93 (9):3266-3281.10.1210/jc.2008-010418552288Open DOISearch in Google Scholar

56. CALHOUN DA, JONES D, TEXTOR S, GOFF DC, MURPHY TP, TOTO RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. Circulation 2008; 117 (25):e510-e526.10.1161/CIRCULATIONAHA.108.18914118574054Search in Google Scholar

57. MATTSSON C, YOUNG WF. Primary aldosteronism: diagnostic and treatment strategies. Nature Clinical Practice Nephrology 2006; 2 (4):198-208.10.1038/ncpneph015116932426Open DOISearch in Google Scholar

58. YOUNG WF, JR. Minireview: primary aldosteronism--changing concepts in diagnosis and treatment. Endocrinology 2003; 144 (6):2208-13.10.1210/en.2003-027912746276Search in Google Scholar

59. YOUNG JR WF. Adrenalectomy for primary aldosteronism; authors’ reply. Ann Intern Med 2003; 138:157-159.10.7326/0003-4819-138-2-200301210-00024Search in Google Scholar

60. EISENHOFER G, LENDERS JW, LINEHAN WM, WALTHER MM, GOLDSTEIN DS, KEISER HR. Plasma normeta-nephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. New England Journal of Medicine 1999; 340 (24):1872-1879.10.1056/NEJM19990617340240410369850Search in Google Scholar

61. GALATI S-J, SAID M, GOSPIN R, BABIC N, BROWN K, GEER EB, et al. The mount Sinai clinical pathway for the management of pheochromocytoma. Endocrine Practice 2014; 21 (4):368-382.10.4158/EP14036.RA25297659Open DOISearch in Google Scholar

62. FRANCIS IR, GROSS MD, SHAPIRO B, KOROBKIN M, QUINT L. Integrated imaging of adrenal disease. Radiology 1992; 184 (1):1-13.10.1148/radiology.184.1.16090631609063Search in Google Scholar

63. FRANCIS IR, KOROBKIN M, BRODEUR FJ, YUTZY GG, QUINT LE, DUNNICK NR, et al. Pheochromocytoma Differentiation of adrenal adenomas from nonadenomas using CT attenuation values. Radiol Clin North Am 1996; 34 (6):1101-12.Search in Google Scholar

64. EISENHOFER G, GOLDSTEIN DS, WALTHER MM, FRIBERG P, LENDERS JW, KEISER HR, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true-from false-positive test results. The Journal of Clinical Endocrinology & Metabolism 2003; 88 (6):2656-2666.10.1210/jc.2002-03000512788870Open DOISearch in Google Scholar

65. VAN BERKEL A, LENDERS J, TIMMERS H. Diagnosis of endocrine Disease: Biochemical diagnosis of phaeochromocytoma and paraganglioma. European Journal of Endocrinology 2014; 170 (3):R109-R119.10.1530/EJE-13-088224347425Search in Google Scholar

66. MAUREA S, CUOCOLO A, REYNOLDS J, NEUMANN R, SALVATORE M. Diagnostic imaging in patients with paragangliomas. Computed tomography, magnetic resonance and MIBG scintigraphy comparison. The quarterly journal of nuclear medicine: official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR) 1996; 40 (4):365-371.Search in Google Scholar

67. RABER W, RAFFESBERG W, BISCHOF M, SCHEUBA C, NIEDERLE B, GASIC S, et al. Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. Archives of Internal Medicine 2000; 160 (19):2957-2963.10.1001/archinte.160.19.295711041903Search in Google Scholar

68. MITTENDORF EA, EVANS DB, LEE JE, PERRIER ND. Pheochromocytoma: advances in genetics, diagnosis, localization, and treatment. Hematology/oncology clinics of North America 2007; 21 (3):509-525.10.1016/j.hoc.2007.04.01217548037Open DOISearch in Google Scholar

69. YOUNG WF. Primary aldosteronism: renaissance of a syndrome. Clinical endocrinology 2007; 66 (5):607-618.10.1111/j.1365-2265.2007.02775.x17492946Search in Google Scholar

70. SAWKA AM, JAESCHKE R, SINGH RJ, YOUNG JR WF. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. The Journal of Clinical Endocrinology & Metabolism 2003; 88 (2):553-558.10.1210/jc.2002-02125112574179Open DOISearch in Google Scholar

71. JOHNSON PT, HORTON KM, FISHMAN EK. Adrenal Mass Imaging with Multidetector CT: Pathologic Conditions, Pearls, and Pitfalls 1. Radiographics 2009; 29 (5):1333-1351.10.1148/rg.29509502719755599Open DOISearch in Google Scholar

72. MARINI F, FALCHETTI A, DEL MONTE F, CARBONELL SALA S, TOGNARINI I, LUZI E, et al. Multiple endocrine neoplasia type 2. Orphanet J Rare Dis 2006; 1 (45):4.Search in Google Scholar

73. ERLIC Z, NEUMANN HP. Familial pheochromocytoma. Hormones (Athens) 2009; 8 (1):29-38.10.14310/horm.2002.121919269919Search in Google Scholar

74. National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987. Neurofibromatosis 1988; 1 (3):172-8.Search in Google Scholar

75. HERR K, MUGLIA VF, KOFF WJ, WESTPHALEN AC. Imaging of the adrenal gland lesions. Radiologia brasileira 2014; 47 (4):228-239.10.1590/0100-3984.2013.1762433712325741090Search in Google Scholar

76. BARZON L, SCARONI C, SONINO N, FALLO F, PAOLETTA A, BOSCARO M. Risk factors and long-term follow-up of adrenal incidentalomas. J Clin Endocrinol Metab 1999; 84 (2):520-6.10.1210/jc.84.2.520Search in Google Scholar

77. MORELLI V, REIMONDO G, GIORDANO R, DELLA CASA S, POLICOLA C, PALMIERI S, et al. Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. The Journal of Clinical Endocrinology & Metabolism 2014; 99 (3):827-834.10.1210/jc.2013-352724423350Search in Google Scholar

78. LOPEZ D, LUQUE-FERNANDEZ MA, STEELE A, ADLER GK, TURCHIN A, VAIDYA A. “Nonfunctional” Adrenal Tumors and the Risk for Incident Diabetes and Cardiovascular Outcomes. A Cohort Study “Nonfunctional” Adrenal Tumors and Risk for Incident Diabetes. Annals of internal medicine 2016; 165 (8):533-542.10.7326/M16-0547545363927479926Search in Google Scholar

79. PAPANASTASIOU L, ALEXANDRAKI KI, ANDROULAKIS, II, FOUNTOULAKIS S, KOUNADI T, MARKOU A, et al. Concomitant alterations of metabolic parameters, cardiovascular risk factors and altered cortisol secretion in patients with adrenal incidentalomas during prolonged follow-up. Clin Endocrinol (Oxf); 86 (4):488-498.10.1111/cen.13294Search in Google Scholar

80. SALCUNI AS, MORELLI V, VAINICHER CE, PALMIERI S, CAIROLI E, SPADA A, et al. Adrenalectomy reduces the risk of vertebral fractures in patients with monolateral adrenal incidentalomas and subclinical hypercortisolism. European Journal of Endocrinology 2016; 174 (3):261-269.10.1530/EJE-15-0977Search in Google Scholar

81. TUNA MM, IMGA NN, DOGAN BA, YILMAZ FM, TOPCUOGLLU C, AKBABA G, et al. Non-functioning adrenal incidentalomas are associated with higher hypertension prevalence and higher risk of atherosclerosis. Journal of endocrinological investigation 2014; 37 (8):765-768.10.1007/s40618-014-0106-5Search in Google Scholar

82. YE Y-L, YUAN X-X, CHEN M-K, DAI Y-P, QIN Z-K, ZHENG F-F. Management of adrenal incidentaloma: the role of adrenalectomy may be underestimated. BMC surgery 2016; 16 (1):41.10.1186/s12893-016-0154-1Search in Google Scholar

83. FONTANA D, PORPIGLIA F, DESTEFANIS P, FIORI C, ALI A, TERZOLO M, et al. What is the role of ultrasonography in the follow-up of adrenal incidentalomas? Urology 1999; 54 (4):612-616.10.1016/S0090-4295(99)00226-5Open DOISearch in Google Scholar

84. MULATERO, P., RABBIA F, MILAN A, PAGLIERI C, MORELLO F, CHIANDUSSI L, VEGLIO F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40 (6):897-902.10.1161/01.HYP.0000038478.59760.4112468576Open DOISearch in Google Scholar